Nuclea Biotechnologies, Inc.
Records under this name other than the patents Nuclea Biotechnologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Nuclea Biotechnologies, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,897,354 | Kinase peptides and antibodies Lapsed on the fee record Ended Mar 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2023 | From the USPTO record |
| US 8,900,820 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors Lapsed on the fee record Ended Dec 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 2, 2022 | From the USPTO record |
| US 9,739,781 | Anti-phospho-Akt antibodies Lapsed on the fee record Ended Aug 22, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 22, 2021 | From the USPTO record |
| US 9,732,158 | Antibodies against fatty acid synthase Lapsed on the fee record Ended Aug 15, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 15, 2021 | From the USPTO record |
| US 6,534,307 | Frozen tissue microarrayer Term ended Term ended Jun 28, 2021 · From the USPTO record | Term ended | Term ended Jun 28, 2021 | From the USPTO record |
| US 8,129,125 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors Lapsed on the fee record Ended Mar 6, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 6, 2020 | From the USPTO record |
| US 9,056,919 | USP2A Peptides and Antibodies Lapsed on the fee record Ended Jun 16, 2019 · High confidence | Lapsed on the fee record | Ended Jun 16, 2019 | High confidence |
| US 9,029,512 | Anti-phospho-Akt antibodies Lapsed on the fee record Ended May 12, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 12, 2019 | From the USPTO record |
| US 8,729,239 | Antibodies against fatty acid synthase Lapsed on the fee record Ended May 20, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 20, 2018 | From the USPTO record |
| US 8,685,891 | Method and assay for determining FAS expression Lapsed on the fee record Ended Apr 1, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 1, 2018 | From the USPTO record |